Clinical Trial Update: Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies [Phase 2]

View source ↗

Summary

Phase II study evaluating CD5 CAR-engineered IL-15-transduced cord blood-derived NK cells combined with lymphodepleting chemotherapy for aggressive T-cell hemat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• T-cell Hematologic Malignancies

Drugs mentioned

• CD5 CAR-engineered IL-15-transduced cord blood-derived NK cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematological Malignancies | Phase 2 | Status: NOT_YET_RECRUITING